Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2025-11-26 00:00:00 ET · period of report 2025-11-25 · accession 0002064832-25-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-26 | 2025-11-25 | ENTA | Trout Harry R. III | See Remarks | A - Grant | $0.00 | +6,463 | 17.4K | +59% | $0 |
| D | 2025-11-26 | 2025-11-25 | ENTA | Trout Harry R. III | See Remarks | A - Grant | $0.00 | +12.9K | 12.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-25 | A | A | 6,463 | $0.00 | 17,375 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-11-25 | A | A | 12,925 | $0.00 | 12,925 | D | $13.66 · — to 2035-11-25 | 12,925 Common Stock | (F2) Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025). |